Innovation

Vaccines: our history, our legacy

Merck and its legacy companies have been working to discover and develop vaccines for more than a century.

April 10, 2016

Share this article

article hero thumbnail

"An epidemic of diphtheria is almost inevitable here. Stop. I am in urgent need of one million units of diphtheria antitoxin. Stop. Mail is only form of transportation. Stop."

Dr. Curtis Welch

This was the desperate radio telegram in January 1925 from Dr. Curtis Welch in Nome, Alaska, to all the major Alaska towns, to territorial Governor Scott Bone in Juneau, and to the U.S. Public Health Service in Washington, D.C. Diphtheria was spreading through the icebound community. Children had already died, and the local supply of diphtheria antitoxin had expired the previous summer.

icon
674 Miles
icon
5 Days
icon
300,000 Units
vaccines history vials

More than a century of vaccines

In 1895, the H.K. Mulford Company began marketing the first commercially available diphtheria antitoxin produced in the U.S., the very medication that helped avert the diphtheria epidemic in Nome. Today, Merck has a significant presence in vaccine discovery, development and distribution in both human and animal health.

Dr. Maurice Hilleman

The vaccine pioneers

Merck’s Dr. Maurice Hilleman belongs to a distinguished group of vaccine pioneers — including Edward Jenner, Louis Pasteur, Jonas Salk and Albert Sabin. Dr. Hilleman is credited with helping to develop more than forty vaccines and his impact on public health is undeniable.

Vaccines are not just for children

The CDC considers immunizations one of the ten great public health achievements of the 20th century. In the U.S., vaccines are now available for a number of infectious diseases that once routinely affected individuals in all age groups. Many people think vaccines are for children, but adults also are susceptible to many infectious diseases. Each year in the U.S., thousands of adults suffer complications from diseases for which there are vaccines. In developing areas of the world, the toll is most often higher.

Vaccine image

Protecting public health is a worldwide challenge

Outside the U.S., Merck is working with national health ministries and non-government agencies to help write new chapters in the public health success story through partnerships, demonstration projects, donation programs, and technology transfer agreements.

“Vaccines are a powerful force of health and health development, and their globalization is not just a business necessity but a public health obligation. Merck is on a mission to ensure that more people can access our vaccines, regardless of where they live or their financial circumstances.”

Julie L. Gerberding M.D., M.P.H.

executive vice president & chief patient officer, Merck

Previous
Next